Andrew Mok

Q: What is Andrew Mok's success rate?

Andrew Mok currently has a success rate of 92.07986763836382.

Q: What is the average return of Andrew Mok's calls?

Their stock ratings have generated an average return of 21.172835237999205.

Barclays | Healthcare

Andrew Mok is an analyst from Barclays specializing in the Healthcare sector. Ranked #1112 out of 4786 analysts, they have issued 118 stock ratings with a success rate of 92.08% and an average return of 21.17%.

Andrew Mok has a well-established track record, with 118 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 92.08% and an average return of 21.17%, underscoring their expertise and ability to identify winning opportunities for investors.

#1112

Out of 4786

118

Total Ratings

+92.08%

Success Rate

+21.17%

Average Return

Recent Ratings Analysis

HUM

Buy

Sep 25, 2026

Target

$515.00

Current

$398.13

Performance

0.05%

Andrew Mok rated HUM as Overweight on Sep 25, 2026, setting a price target of 515. Shares have remained stable near 398.13, leaving the 515 target still in play.

DVA

Hold

Aug 05, 2026

Target

$224.00

Current

$178.47

Performance

-5.42%

On Aug 05, 2026, DVA was given a Equal-Weight rating by Andrew Mok, with a target price of 224. The rating provided protection from downside risk as the stock fell to 178.47.

CI

Hold

Jul 31, 2026

Target

$310.00

Current

$272.01

Performance

-2.52%

CI received a Equal-Weight rating from Andrew Mok on Jul 31, 2026, aiming for 310. Shares remained flat at 272.01, aligning with the neutral rating.

ACHC

Hold

Jul 30, 2026

Target

$32.00

Current

$28.09

Performance

-0.18%

On Jul 30, 2026, Andrew Mok published a Equal-Weight outlook on ACHC, with a target of 32. Sideways action left the Hold view intact, with no major move since 28.09.

CNC

Buy

Jul 29, 2026

Target

$80.00

Current

$61.80

Performance

-0.03%

Andrew Mok on Jul 29, 2026 assigned CNC a Overweight rating, with a price target of 80. The recommendation remains pending validation as shares consolidate around 61.8.

UHS

Hold

Jul 28, 2026

Target

$168.00

Current

$178.86

Performance

7.60%

On Jul 28, 2026, Andrew Mok reaffirmed UHS with a Equal-Weight rating, targeting 168. Market strength beyond 178.86 went further than the conservative outlook suggested.

HCA

Hold

Jul 27, 2026

Target

$387.00

Current

$435.61

Performance

11.80%

HCA was rated Equal-Weight by Andrew Mok on Jul 27, 2026, with a price objective of 387. Despite caution, upside momentum rewarded risk-takers with gains to 435.61.

THC

Buy

Jul 24, 2026

Target

$271.00

Current

$259.71

Performance

11.37%

On Jul 24, 2026, Andrew Mok initiated coverage on THC with a Overweight rating and target of 271. The stock’s climb of 11.37% since the call highlights the foresight in the rating.

MOH

Sell

Jul 24, 2026

Target

$180.00

Current

$190.79

Performance

-3.42%

Andrew Mok issued a Underweight recommendation for MOH on Jul 24, 2026, price target set at 180. Investors remain in wait-and-see mode as shares stayed flat.

CYH

Sell

Jul 23, 2026

Target

$2.50

Current

$2.94

Performance

5.76%

On Jul 23, 2026, CYH was evaluated by Andrew Mok, who gave a Underweight rating and target of 2.5. Investors benefited from heeding the Sell stance, avoiding a 5.76% decline.

UNH

Buy

Jul 20, 2026

Target

$441.00

Current

$376.59

Performance

-10.67%

Andrew Mok rated UNH as Overweight on Jul 20, 2026, setting a price target of 441. The stock has underperformed, dropping 10.67% despite the bullish target of 441.

ELV

Buy

Jul 16, 2026

Target

$457.00

Current

$396.09

Performance

6.23%

On Jul 16, 2026, ELV was given a Overweight rating by Andrew Mok, with a target price of 457. The stock rallied 6.23% after the rating, narrowing the gap to the target of 457 and validating the bullish stance.

AVAH

Buy

Jul 09, 2026

Target

$9.50

Current

$12.41

Performance

26.37%

AVAH received a Overweight rating from Andrew Mok on Jul 09, 2026, aiming for 9.5. Momentum has favored the Buy call, with shares climbing from 12.41 to 12.41, rewarding those who trusted the recommendation.

ADUS

Sell

Jul 09, 2026

Target

$96.00

Current

$113.19

Performance

3.16%

On Jul 09, 2026, Andrew Mok published a Underweight outlook on ADUS, with a target of 96. The rating remains inconclusive as the market consolidates near 113.19.

OSCR

Buy

Jun 10, 2026

Target

$35.00

Current

$29.60

Performance

6.28%

Andrew Mok on Jun 10, 2026 assigned OSCR a Overweight rating, with a price target of 35. The Buy call aligned well with market performance, producing a gain of 6.28%.

AGL

Hold

May 26, 2026

Target

$81.00

Current

$80.73

Performance

-5.32%

On May 26, 2026, Andrew Mok reaffirmed AGL with a Equal-Weight rating, targeting 81. The Hold stance reflected market caution that was later justified.

PRVA

Hold

May 26, 2026

Target

$24.00

Current

$19.71

Performance

-11.22%

PRVA was rated Equal-Weight by Andrew Mok on May 26, 2026, with a price objective of 24. Investors who stayed cautious avoided some of the 11.22% decline.

CVS

Buy

May 26, 2026

Target

$106.00

Current

$89.13

Performance

-1.76%

On May 26, 2026, Andrew Mok initiated coverage on CVS with a Overweight rating and target of 106. Neutral price movement of -1.76% leaves room for interpretation.

ALHC

Hold

May 26, 2026

Target

$16.00

Current

$8.21

Performance

-48.78%

Andrew Mok issued a Equal-Weight recommendation for ALHC on May 26, 2026, price target set at 16. Market action validated the conservative Hold outlook with shares at 8.21.

ASTH

Buy

May 26, 2026

Target

$50.00

Current

$36.37

Performance

-5.63%

On May 26, 2026, ASTH was evaluated by Andrew Mok, who gave a Overweight rating and target of 50. Investors saw limited payoff as shares fell short of the 50 target.

LMRI

Buy

May 20, 2026

Target

$9.00

Current

$10.21

Performance

37.97%

Andrew Mok rated LMRI as Overweight on May 20, 2026, setting a price target of 9. The call has proven timely, with shares rising 37.97% toward the price target of 9.

RDNT

Buy

May 20, 2026

Target

$65.00

Current

$70.79

Performance

30.58%

On May 20, 2026, RDNT was given a Overweight rating by Andrew Mok, with a target price of 65. The stock rallied 30.58% after the rating, narrowing the gap to the target of 65 and validating the bullish stance.

EHC

Buy

May 05, 2026

Target

$140.00

Current

$123.47

Performance

17.41%

EHC received a Overweight rating from Andrew Mok on May 05, 2026, aiming for 140. Momentum has favored the Buy call, with shares climbing from 123.47 to 123.47, rewarding those who trusted the recommendation.

SGRY

Hold

Mar 03, 2026

Target

$18.00

Current

$14.40

Performance

3.45%

On Mar 03, 2026, Andrew Mok published a Equal-Weight outlook on SGRY, with a target of 18. Sideways action left the Hold view intact, with no major move since 14.4.

BKD

Buy

Feb 03, 2026

Target

$18.00

Current

$11.11

Performance

-29.86%

Andrew Mok on Feb 03, 2026 assigned BKD a Overweight rating, with a price target of 18. The call has struggled to gain traction, with shares losing 29.86%.

Frequency Asked Questions

Who is Andrew Mok?

Andrew Mok is an analyst from Barclays specializing in the Healthcare sector.

What is Andrew Mok's success rate?

Andrew Mok currently has a success rate of +92.08%.

How many ratings has Andrew Mok issued?

Andrew Mok has issued 118 stock ratings so far.

What is the average return of Andrew Mok's calls?

Their stock ratings have generated an average return of +21.17%.

What is Andrew Mok's ranking?

Andrew Mok is ranked #1112 out of 4786 analysts.

What types of ratings does Andrew Mok give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Andrew Mok?

You can follow Andrew Mok by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Andrew Mok?

Their latest rating was a Buy on HUM issued on 2026-09-25.